Virpax Pharmaceuticals (VRPX) Competitors $1.61 -0.33 (-17.01%) Closing price 04:00 PM EasternExtended Trading$1.62 +0.01 (+0.37%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VRPX vs. NXTC, MIRA, BCAB, GLYC, CARM, EDSA, COCP, BFRG, LPTX, and NRSNShould you be buying Virpax Pharmaceuticals stock or one of its competitors? The main competitors of Virpax Pharmaceuticals include NextCure (NXTC), MIRA Pharmaceuticals (MIRA), BioAtla (BCAB), GlycoMimetics (GLYC), Carisma Therapeutics (CARM), Edesa Biotech (EDSA), Cocrystal Pharma (COCP), Bullfrog AI (BFRG), Leap Therapeutics (LPTX), and NeuroSense Therapeutics (NRSN). These companies are all part of the "pharmaceutical products" industry. Virpax Pharmaceuticals vs. NextCure MIRA Pharmaceuticals BioAtla GlycoMimetics Carisma Therapeutics Edesa Biotech Cocrystal Pharma Bullfrog AI Leap Therapeutics NeuroSense Therapeutics NextCure (NASDAQ:NXTC) and Virpax Pharmaceuticals (NASDAQ:VRPX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, community ranking, profitability, risk, analyst recommendations, dividends and media sentiment. Does the MarketBeat Community prefer NXTC or VRPX? NextCure received 79 more outperform votes than Virpax Pharmaceuticals when rated by MarketBeat users. Likewise, 65.08% of users gave NextCure an outperform vote while only 60.00% of users gave Virpax Pharmaceuticals an outperform vote. CompanyUnderperformOutperformNextCureOutperform Votes8265.08% Underperform Votes4434.92% Virpax PharmaceuticalsOutperform Votes360.00% Underperform Votes240.00% Which has higher earnings and valuation, NXTC or VRPX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNextCureN/AN/A-$62.72M-$1.98-0.29Virpax PharmaceuticalsN/AN/A-$15.19MN/AN/A Do institutionals & insiders hold more shares of NXTC or VRPX? 42.7% of NextCure shares are held by institutional investors. Comparatively, 32.2% of Virpax Pharmaceuticals shares are held by institutional investors. 13.3% of NextCure shares are held by insiders. Comparatively, 3.7% of Virpax Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is NXTC or VRPX more profitable? NextCure's return on equity of -62.50% beat Virpax Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets NextCureN/A -62.50% -53.67% Virpax Pharmaceuticals N/A -1,554.34%-338.29% Which has more volatility and risk, NXTC or VRPX? NextCure has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Comparatively, Virpax Pharmaceuticals has a beta of 0.96, indicating that its share price is 4% less volatile than the S&P 500. Do analysts recommend NXTC or VRPX? NextCure currently has a consensus price target of $3.50, indicating a potential upside of 515.11%. Virpax Pharmaceuticals has a consensus price target of $75.00, indicating a potential upside of 4,558.39%. Given Virpax Pharmaceuticals' higher probable upside, analysts clearly believe Virpax Pharmaceuticals is more favorable than NextCure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NextCure 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Virpax Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media prefer NXTC or VRPX? In the previous week, Virpax Pharmaceuticals had 6 more articles in the media than NextCure. MarketBeat recorded 7 mentions for Virpax Pharmaceuticals and 1 mentions for NextCure. Virpax Pharmaceuticals' average media sentiment score of 0.39 beat NextCure's score of 0.00 indicating that Virpax Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment NextCure Neutral Virpax Pharmaceuticals Neutral SummaryNextCure beats Virpax Pharmaceuticals on 8 of the 13 factors compared between the two stocks. Remove Ads Get Virpax Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VRPX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRPX vs. The Competition Export to ExcelMetricVirpax PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$42.77M$6.99B$5.68B$8.30BDividend YieldN/A2.72%4.55%4.02%P/E RatioN/A7.2324.5519.25Price / SalesN/A230.77395.7294.09Price / CashN/A65.6738.1634.64Price / Book0.986.617.064.46Net Income-$15.19M$142.13M$3.19B$247.07M7 Day Performance-50.46%2.79%1.49%3.05%1 Month Performance-73.73%2.70%5.87%-2.85%1 Year Performance-98.28%-4.42%14.94%4.63% Virpax Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRPXVirpax Pharmaceuticals2.2737 of 5 stars$1.61-17.0%$75.00+4,558.4%-98.1%$42.77MN/A0.007Gap DownHigh Trading VolumeNXTCNextCure3.9837 of 5 stars$0.64-7.0%$3.50+446.4%-67.9%$17.94MN/A-0.3190MIRAMIRA Pharmaceuticals1.4953 of 5 stars$1.08-8.5%$14.00+1,196.3%+0.0%$17.89MN/A-1.932News CoverageBCABBioAtla3.1696 of 5 stars$0.36+4.9%$6.00+1,564.4%-84.6%$17.43M$11M-0.2160GLYCGlycoMimetics3.6447 of 5 stars$0.27+2.1%$8.00+2,870.7%-91.0%$17.37M$10,000.000.0050Analyst ForecastCARMCarisma Therapeutics2.6137 of 5 stars$0.41+0.8%$4.94+1,092.7%-83.9%$17.29M$20.27M-0.2720News CoverageEDSAEdesa Biotech3.5462 of 5 stars$2.44+2.1%$21.00+760.7%-40.2%$17.06MN/A-1.3020Positive NewsCOCPCocrystal Pharma1.8979 of 5 stars$1.66+0.9%$7.00+321.7%+3.3%$16.89MN/A-0.9010Upcoming EarningsNews CoverageGap DownBFRGBullfrog AI0.4555 of 5 stars$1.89+9.9%N/A-46.5%$16.47M$60,000.00-2.224News CoverageLPTXLeap Therapeutics1.7788 of 5 stars$0.42+6.2%$4.92+1,057.4%-84.5%$16.28MN/A-0.2240Upcoming EarningsGap UpNRSNNeuroSense Therapeutics0.6211 of 5 stars$1.18-0.4%N/A-38.6%$16.07MN/A-1.8410 Remove Ads Related Companies and Tools Related Companies NXTC Alternatives MIRA Alternatives BCAB Alternatives GLYC Alternatives CARM Alternatives EDSA Alternatives COCP Alternatives BFRG Alternatives LPTX Alternatives NRSN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VRPX) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virpax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Virpax Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VRPX Stock Free VRPX Stock Alerts